Oceania Healthcare (OCA) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
8 Jul, 2026Executive summary
Achieved a significant turnaround with improved sales, cost efficiencies, and disciplined capital management, including a 5% increase in sales volumes and strong presales at key developments.
Realized $4 million in cost savings in 1HY26, with $13.2 million on track for FY26 and annualized cost savings of $20.4 million identified.
Gearing reduced to 34.8%, within the 30–35% target range, and divestments of four sites are progressing for completion in FY26.
Operating cash flow strengthened, positioning the business for further improvement in the second half.
Integrated care model and strategic focus on sales, business excellence, and capital management drive improved results.
Financial highlights
Total comprehensive income rose to $40.4 million, up $28.6 million year-over-year, driven by property revaluations and improved operational performance.
Proforma underlying EBITDA increased 23.2% to $41.9 million, and proforma underlying NPAT rose 18.9% to $24.1 million.
Operating cash flow grew 12.2% to $79.0 million, and net tangible assets per share increased 3.8% to $1.57.
Net debt decreased to $608.9 million, with $116 million headroom on facilities and total assets surpassing $3.0 billion.
No interim dividend declared, with focus on free cash flow sustainability before resuming payments.
Outlook and guidance
FY26 remains a stabilization year, with focus on lifting sales cadence, reducing unsold and aged stock, and delivering $13.2 million in targeted savings.
Targeting full recovery of development costs at The Helier by March 2026 and completion of Stage One at Franklin, with four divestments targeting $40 million in capital release.
Management expects at least similar or higher sales volumes in the second half, with strong application momentum supporting settlements.
Plans to implement $20.4 million in annualized cost-out initiatives from FY27 and return to positive free cash flow before resuming dividends.
Development activity will be paced to market conditions, targeting 100–150 units per year.
Latest events from Oceania Healthcare
- Strong financial growth, reinvestment, and innovation highlighted at the AGM.OCA
AGM 20248 Jul 2026 - EBITDA up, cash flow strong, but net profit down; sales and debt reduction remain key priorities.OCA
H1 20258 Jul 2026 - Secured bond offer funds growth and debt reduction, with record FY26 results and strong sustainability.OCA
Investor presentation21 Jun 2026 - EBITDA up 4.1%, sales volumes up 9.2%, and cost savings of up to $20m targeted.OCA
H2 202516 Jun 2026 - Record sales, EBITDA growth, and debt reduction position for positive cash flow in FY27.OCA
H2 202622 May 2026 - Asset and sales growth, no FY25 dividend, and focus on efficiency and sustainability.OCA
AGM 20253 Feb 2026 - Disciplined execution and service innovation drive sustainable growth and returns to FY31.OCA
Investor Day 2025 Presentation15 Sep 2025 - Underlying EBITDA rose 4.1% as sales volumes and operational efficiency both improved.OCA
Investor Presentation1 Jul 2025 - Refinancing, sales growth, and divestments drive debt reduction and operational optimisation.OCA
Investor Presentation1 Jul 2025